Experimental and clinical cardiology (Exp Clin Cardiol )

Publisher: International Academy of Cardiovascular Sciences, Pulsus

Description

Experimental and Clinical Cardiology, an international English language journal, will consider for publication original articles, short communications, letters to the editor, editorials and mini-reviews. Emphasis is given to all aspects of the cardiovascular system from basic science to clinical cardiology. Submissions will be assessed primarily on their scientific validity and merit, not on their grammatical quality. Manuscripts are received with the understanding that they are submitted solely to Experimental and Clinical Cardiology, and that none of the material contained in the manuscript has been published previously or is under consideration for publication elsewhere, excluding abstracts. The publisher reserves copyright in any medium on all published material, and material may not be reproduced without the written permission of the publisher. Statements and opinions are the responsibility of the authors.

  • Impact factor
    1.10
  • 5-year impact
    0.00
  • Cited half-life
    5.40
  • Immediacy index
    0.03
  • Eigenfactor
    0.00
  • Article influence
    0.00
  • Website
    Experimental and Clinical Cardiology website
  • Other titles
    Experimental and clinical cardiology (Online), Cardiology
  • ISSN
    1918-1515
  • OCLC
    67618076
  • Material type
    Document, Periodical, Internet resource
  • Document type
    Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Pulsus

  • Pre-print
    • Author cannot archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Conditions
    • All articles are available from PubMed Central and open access on publisher website 12 months after publication
    • Papers funded by CIHR are made open access 6 months after publication
    • Publisher last contacted on 10/12/2012
  • Classification
    ​ white

Publications in this journal

  • Experimental and clinical cardiology 09/2014; 20(10):6258-6270.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To optimally improve health status after a myocardial infarction it is essential for patients to understand the seriousness of the disease and improve their self-management. Aims: To describe patients’ perceptions of preventive care, after experiencing a first episode of an acute myocardial infarction in a central hospital in Portugal and to analyze the intent to change behaviors and real changes six months after myocardial infarction. Methods: Longitudinal descriptive study; 106 patients aged between 35 and 64 years, who had cardiovascular risk factors and a first experience of myocardial infarction were selected. Data was collected in two structured interviews. Results: Of the patients, 18% had never, by their own accord, chosen to use preventive care services. During hospitalization, 43% described preventive care as a negative perception. Patients showed intent to change their habits but after discharge, they had difficulties in self-management of disease, maintaining monitoring or changing their cardiovascular risk factors such as physical activity (41%), blood pressure (37%), and eating habits (24%). Conclusions: There were considerable discrepancies between the intention and action in behavioral changes in patients after a myocardial infarction. Regarding the patients’ perceptions, there is a need to improve their involvement in the management of disease.
    Experimental and clinical cardiology 08/2014; 20(8).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Elevated levels of aldosterone are associated with deleterious effects on the cardiovascular system, which contributes to the development of endothelial dysfunction, fibrosis and inflammation hypertrophy, heart failure, sympathetic activation, stroke and renal dysfunction. Furthermore, it has been shown that treatment with mineralocorticoid receptor antagonists reduce the progressive damage that occurs in aldosterone target organs of patients with hypertension or heart failure, both in humans and in dogs; however, the expression of such receptors has only been demonstrated in human cardiac tissues, rabbit and rat, not so in the dog. To determine the expression of aldosterone receptors in cardiac tissues of healthy dogs, we employ the technique of immunohistochemistry for positive labeling with specific antibody in the hearts of two clinically healthy beagle dogs. Immunohistochemical assays performed, showed for first time, unpublished results of positive immunoreactivity to aldosterone receptors in dogs. This study concludes that the presence of aldosterone receptors in the heart of healthy dogs, given the existing cardio-renal axis similar to human and allows us to propose new research to test their possible alterations and pharmacological manipulation in the treatment of myocardial fibrosis reversibility using antagonists of these receptors.
    Experimental and clinical cardiology 08/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Coronary heart disease (CHD) is the single largest killer out of all diseases in Europe and in the US. Pathologic cardiac ischemia in CHD triggers a succession of events leading to massive destruction and loss of cardiac tissues. Thus, replacement of the damaged cardiac tissues by newly regenerated myocardium would be a therapeutic ideal for pathology modifying treatment of CHD. The aim of this study was to evaluate the ability of an active fraction isolated from Chinese herb Rosa laevigata Michx (aFRLM) in therapeutic cardiomyogenesis through promoting substantial regeneration of cardiac tissues in a myocardial infarction (MI) animal model. Our results demonstrated that oral administration of aFRLM to MI animals could significantly improve cardiac functional performance and induce myocardial regeneration replacing the necrosed cardiac tissues in a sub-clinical MI animal model. The property of the aFRLM appears to be entirely novel and may provide a potential therapeutic alternative for MI treatment.
    Experimental and clinical cardiology 08/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aims: to assess the diagnostic value of plasma D-dimer level assay for prediction of thrombus formation in left atrial appendage( LAA) in patients with moderate or severe mitral stenosis Methods and results: We enrolled 218 patients with isolated rheumatic mitral stenosis who were candidates for commissurotomy. Trans-esophageal echocardiography and D-dimer plasma level measurement was done in all patients. Forty five percent of the patients were in sinus rhythm. Patient with a thrombus in LAA had higher levels of D-dimer than those with without thrombus (median of 691.50 and inter-quartile range of 370.5-1839.5 vs. median of 347μg/dl and inter-quartile range: 216-642, p: 0.002). Receiver operating curve analysis yielded an optimal D-dimer cut-off level of 2100 μg/dl for detection of thrombus. This cut-off level has been associated with a specificity of 95% and a negative predictive value of 88% for the presence of thrombus in LAA. Conclusion: In rheumatic mitral stenosis, D-dimer level assay has a high specificity and negative predictive value for evaluation of clot formation in LAA. This remarkable diagnostic yield may have clinical implications. Keywords: D-dimer, thrombus, mitral stenosis
    Experimental and clinical cardiology 07/2014; 20(7):1808-1818/2014.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract MicroRNAs (miRNAs) are critical regulators of most major cellular processes and seem to play a vital role in the pathogenesis of numerous diseases including atrial fibrillation, the most commonly encountered cardiac rhythm disorder. Among the several miRNAs that appear to be involved in pathogenesis of atrial fibrillation, miRNA 208a is linked to fibrosis and proper cardiac conduction. We quantified the expression levels of miRNA 208a in left atrial appendage tissue of patients with paroxysmal (n=2), persistent (n=10), and long-standing persistent (n=7) arrhythmia using quantitative PCR. In paroxysmal atrial fibrillation, miRNA 208a was expressed moderately, whereas the expression was enhanced in persistent atrial fibrillation and significantly reduced in long-standing persistent atrial fibrillation. The difference between persistent and long-standing persistent atrial fibrillation was significant at p=0.02. The findings from our study suggest a decline in miRNA 208a expression with ongoing arrhythmia, possibly preceded by a rise in expression from paroxysmal to persistent atrial fibrillation or even long-standing persistent. The significant changes in miRNA 208a expression over the course of the disease may be used as an additional diagnostic tool to monitor the progression of atrial fibrillation.
    Experimental and clinical cardiology 07/2014;
  • Experimental and clinical cardiology 06/2014; 20(5):3447-3451.